Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
It is a a randomized, controlled, crossover trial studying 26.6 g/day digestible maize starch (DMS) (i.e., control) vs 66.6 g/day high‐amylose maize starch (HMS: 60% RS and 40% DS) vs 57.2 g/day native banana starch (NBS: 70.5% RS and 10% DS) in seventeen recruited participants with Type 2 Diabetes (T2D) (1)
Continuous glucose monitoring (CGM): glycemic control (GC) and glycemic variability (GV)
High‐amylose maize starch (HMS: 60% RS and 40% DS) and native banana starch (NBS: 70.5% RS and 10% DS) raised 24-hour mean blood glucose occurring during days 2 to 4 (p < 0.05). On day 4, HMS had higher CONGA, GRADE, and J-index values than digestible maize starch (DMS) (p < 0.05). NBS intake reduced fasting glyce…